

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**February 5, 2026**

---

**I New Study - Initial Review**

**A082302**, Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (Version Date 12/04/25)

---

**II New Study - Initial Review**

**S1900N**, A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) (Version Date 12/01/25)

---

**III New Study - Initial Review**

**S2419**, Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial] (Version Date 12/17/25)

---

**IV Amendment**

**S2005**, A Phase II Randomized Study Comparing BTK Inhibitors (Ibrutinib plus Rituximab or Zanubrutinib alone) vs. BCL-2 Inhibitor (Venetoclax) and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma (LPL) (Version Date 12/01/25)

---

**V Continuing Review**

**S2200**, A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2) (Version Date 07/15/25)

## **VI Continuing Review**

**S2207**, Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma (Version Date 04/07/25)

---

## **VII Continuing Review**

**S2210**, A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations (Version Date 06/07/23)

---

## **VIII Continuing Review**

**A041703**, A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly-Diagnosed Older Adults or Adults with Relapsed or Refractory disease and Feasibility Study of Ponatinib with Inotuzumab Ozogamicin Followed by Ponatinib with Blinatumomab for Ph-Positive CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly-Diagnosed Older Adults (Version Date 10/30/25)

---

## **IX Continuing Review**

**A082002**, A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or without Radiation Therapy for PD-L1-Negative, Advanced Non-small Cell Lung Cancer (Version Date 08/01/25)

---

## **X Continuing Review**

**E1A11**, Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) (Version Date 10/21/20)

---

## **XI Continuing Review**

**EA8211**, Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR) (Version Date 08/01/25)

---

## **XII Continuing Review**

**GOG-0262**, A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel In Combination With Carboplatin With Or Without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #113912) in the Treatment of Primary Stage II, III OR IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging To Evaluate Treatment Response in Patients Participating in GOG-0262 (Version Date 11/07/18)

---

## **XIII Continuing Review**

**AMC-107**, A Phase 2 Trial of Ixazomib for Kaposi Sarcoma (Version Date 09/22/22)

---

## **XIV Continuing Review**

**EA2176**, A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients (Version Date 07/25/25)

---

## **XV Continuing Review**

**MM10A-EA02**, A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial (Version Date 11/18/25)

---